Tags

Type your tag names separated by a space and hit enter

A Double-Blind, Randomized Clinical Trial of Niacinamide 4% versus Hydroquinone 4% in the Treatment of Melasma.
Dermatol Res Pract. 2011; 2011:379173.DR

Abstract

Background.

Multiple modalities have been used in the treatment of melasma with variable success. Niacinamide has anti-inflammatory properties and is able to decrease the transfer of melanosomes.

Objective.

To evaluate the therapeutic effect of topical niacinamide versus hydroquinone (HQ) in melasma patients. Patients and Methods. Twenty-seven melasma patients were randomized to receive for eight weeks 4% niacinamide cream on one side of the face, and 4% HQ cream on the other. Sunscreen was applied along the observation period. They were assessed by noninvasive techniques for the evaluation of skin color, as well as subjective scales and histological sections initially and after the treatment with niacinamide.

Results.

All patients showed pigment improvement with both treatments. Colorimetric measures did not show statistical differences between both sides. However, good to excellent improvement was observed with niacinamide in 44% of patients, compared to 55% with HQ. Niacinamide reduced importantly the mast cell infiltrate and showed improvement of solar elastosis in melasma skin. Side effects were present in 18% with niacinamide versus 29% with HQ.

Conclusion.

Niacinamide induces a decrease in pigmentation, inflammatory infiltrate, and solar elastosis. Niacinamide is a safe and effective therapeutic agent for this condition.

Authors+Show Affiliations

Department of Dermatology, Hospital Central, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

21822427

Citation

Navarrete-Solís, Josefina, et al. "A Double-Blind, Randomized Clinical Trial of Niacinamide 4% Versus Hydroquinone 4% in the Treatment of Melasma." Dermatology Research and Practice, vol. 2011, 2011, p. 379173.
Navarrete-Solís J, Castanedo-Cázares JP, Torres-Álvarez B, et al. A Double-Blind, Randomized Clinical Trial of Niacinamide 4% versus Hydroquinone 4% in the Treatment of Melasma. Dermatology research and practice. 2011;2011:379173.
Navarrete-Solís, J., Castanedo-Cázares, J. P., Torres-Álvarez, B., Oros-Ovalle, C., Fuentes-Ahumada, C., González, F. J., Martínez-Ramírez, J. D., & Moncada, B. (2011). A Double-Blind, Randomized Clinical Trial of Niacinamide 4% versus Hydroquinone 4% in the Treatment of Melasma. Dermatology Research and Practice, 2011, 379173. https://doi.org/10.1155/2011/379173
Navarrete-Solís J, et al. A Double-Blind, Randomized Clinical Trial of Niacinamide 4% Versus Hydroquinone 4% in the Treatment of Melasma. Dermatology research and practice. 2011;2011:379173. PubMed PMID: 21822427.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A Double-Blind, Randomized Clinical Trial of Niacinamide 4% versus Hydroquinone 4% in the Treatment of Melasma. AU - Navarrete-Solís,Josefina, AU - Castanedo-Cázares,Juan Pablo, AU - Torres-Álvarez,Bertha, AU - Oros-Ovalle,Cuauhtemoc, AU - Fuentes-Ahumada,Cornelia, AU - González,Francisco Javier, AU - Martínez-Ramírez,Juan David, AU - Moncada,Benjamin, Y1 - 2011/07/21/ PY - 2011/01/16/received PY - 2011/05/16/revised PY - 2011/06/08/accepted PY - 2011/8/9/entrez PY - 2011/8/9/pubmed PY - 2011/8/9/medline SP - 379173 EP - 379173 JF - Dermatology research and practice VL - 2011 N2 - Background. Multiple modalities have been used in the treatment of melasma with variable success. Niacinamide has anti-inflammatory properties and is able to decrease the transfer of melanosomes. Objective. To evaluate the therapeutic effect of topical niacinamide versus hydroquinone (HQ) in melasma patients. Patients and Methods. Twenty-seven melasma patients were randomized to receive for eight weeks 4% niacinamide cream on one side of the face, and 4% HQ cream on the other. Sunscreen was applied along the observation period. They were assessed by noninvasive techniques for the evaluation of skin color, as well as subjective scales and histological sections initially and after the treatment with niacinamide. Results. All patients showed pigment improvement with both treatments. Colorimetric measures did not show statistical differences between both sides. However, good to excellent improvement was observed with niacinamide in 44% of patients, compared to 55% with HQ. Niacinamide reduced importantly the mast cell infiltrate and showed improvement of solar elastosis in melasma skin. Side effects were present in 18% with niacinamide versus 29% with HQ. Conclusion. Niacinamide induces a decrease in pigmentation, inflammatory infiltrate, and solar elastosis. Niacinamide is a safe and effective therapeutic agent for this condition. SN - 1687-6113 UR - https://www.unboundmedicine.com/medline/citation/21822427/A_Double_Blind_Randomized_Clinical_Trial_of_Niacinamide_4_versus_Hydroquinone_4_in_the_Treatment_of_Melasma_ L2 - https://doi.org/10.1155/2011/379173 DB - PRIME DP - Unbound Medicine ER -